Batard Eric, Vibet Marie-Anne, Lemarchand Cathelle, Navas Dominique, Lepelletier Didier, Potel Gilles, Montassier Emmanuel
aEmergency Department bPharmacy cDepartment of Microbiology and Infection Control, Nantes University Hospital dClinical and experimental therapeutics of infections eLaboratory of Mathematics Jean Leray, University of Nantes, Nantes fCentre Henri Lebesgue, France.
Eur J Emerg Med. 2017 Jun;24(3):189-195. doi: 10.1097/MEJ.0000000000000331.
Third-generation cephalosporins and fluoroquinolones are particularly prone to promoting bacterial resistance. Their use in Emergency Departments (EDs) is poorly known. Our objectives were to assess the use of antibacterial agents in French EDs.
This study is a retrospective study of antibiotics delivered to the adult units of 11 EDs of French academic centres in 2012, and to six of these EDs between 2009 and 2012.
The total antibiotic use was 66.4 defined daily doses (DDD)/1000 ED visits in 2012, and it increased between 2009 and 2012 (yearly estimate, +1.8±0.9 DDD/1000 ED visits, P=0.048). The 3GC-FQ class, which grouped third-generation cephalosporins and fluoroquinolones, accounted for 39.2% of the total antibiotic use, and the use of this class of antibiotics was highly variable among EDs (range, 31.6-49.5% of total antibiotic use). The aminopenicillin and β-lactamase inhibitor/3GC-FQ ratio varied among EDs [median (range), 0.91 (0.52-1.25)]. Between 2009 and 2012, there was a significant decrease in the use of the 3GC-FQ class (yearly estimate, -0.8±0.4% of total antibiotic use), antipneumococcal fluoroquinolones (-0.8±0.3%) and other fluoroquinolones (-0.9%±0.3%), and there was a significant increase in the use of third-generation cephalosporins (+0.7±0.3%), aminoglycosides (+0.4±0.1%), imidazole derivatives (+0.4±0.1%) and lincosamides (+0.1±0.0%).
Fluoroquinolones and third-generation cephalosporins are widely used in the ED. Their use is highly variable among EDs. Third-generation cephalosporins were increasingly used between 2009 and 2012, whereas the use of fluoroquinolones decreased. Reduced use of cephalosporins in the ED, without increasing fluoroquinolone use, should be aimed at through antibiotic stewardship programs.
第三代头孢菌素和氟喹诺酮类药物特别容易促使细菌产生耐药性。它们在急诊科(ED)的使用情况鲜为人知。我们的目的是评估法国急诊科抗菌药物的使用情况。
本研究是一项回顾性研究,涉及2012年法国学术中心11个急诊科成人科室所使用的抗生素,以及其中6个急诊科在2009年至2012年期间的使用情况。
2012年抗生素总使用量为66.4限定日剂量(DDD)/1000次急诊就诊,且在2009年至2012年期间有所增加(年度估计值,+1.8±0.9 DDD/1000次急诊就诊,P = 0.048)。将第三代头孢菌素和氟喹诺酮类药物归为一类的3GC - FQ类药物占抗生素总使用量的39.2%,这类抗生素在不同急诊科的使用差异很大(范围为抗生素总使用量的31.6 - 49.5%)。氨基青霉素与β - 内酰胺酶抑制剂/3GC - FQ的比例在不同急诊科有所不同[中位数(范围),0.91(0.52 - 1.25)]。在2009年至2012年期间,3GC - FQ类药物的使用量显著下降(年度估计值,占抗生素总使用量的-0.8±0.4%),抗肺炎球菌氟喹诺酮类药物(-0.8±0.3%)和其他氟喹诺酮类药物(-0.9%±0.3%),而第三代头孢菌素(+0.7±0.3%)、氨基糖苷类药物(+0.4±0.1%)、咪唑衍生物(+0.4±0.1%)和林可酰胺类药物(+0.1±0.0%)的使用量显著增加。
氟喹诺酮类药物和第三代头孢菌素在急诊科广泛使用。它们在不同急诊科的使用差异很大。在2009年至2012年期间,第三代头孢菌素的使用量日益增加,而氟喹诺酮类药物的使用量则有所下降。应通过抗生素管理计划,在不增加氟喹诺酮类药物使用的情况下,减少急诊科头孢菌素的使用。